The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.

@article{Eda2010ThePI,
  title={The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.},
  author={Homare Eda and Katsuhiko Aoki and Soki Kato and Yutaka Okawa and Koji Takada and Takaaki Tanaka and Keishi Marumo and Kiyoshi Ohkawa},
  journal={European journal of haematology},
  year={2010},
  volume={85 1},
  pages={
          68-75
        }
}
OBJECTIVES Bortezomib (PS-341; Velcade), a proteasome inhibitor, is used as a therapeutic agent for multiple myeloma. Bortezomib has been shown to strongly induce osteoblast differentiation and elevate the levels of osteoblast-related differentiation markers in the serum of patients with myeloma. Bortezomib also reportedly increases the activity of the transcription factor, Runx2. However, the mechanism of action by which bortezomib-elevated Runx2 activity mediates osteoblast differentiation… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Crosstalk between cancer cells and bone microenvironment in bone metastasis.

  • Biochemical and biophysical research communications
  • 2005
VIEW 2 EXCERPTS